Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and ...

A benefit for local musician and worship pastor Chris Robbins will be held at the Friedhof Building Sunday, Sept. 29, from ...

Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead ...